IN8bio (INAB) said Tuesday that new data from the ongoing early-stage study of INB-100 showed that 100% of acute myeloid leukemia patients in the original and expansion groups through Jan. 17 remained in complete remission.
The company said INB-100, which is designed to help patients with complex leukemias, such as AML, also showed improved survival compared with standard treatment.
The investigational therapy also "appears to be well-tolerated" and has no significant effect on patient quality of life, the company said.
Shares of IN8bio were up 71% in recent premarket activity on Tuesday.
Price: 0.4797, Change: +0.21, Percent Change: +77.60
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。